

FAX RECEIVED


2002

GROUP 1600

Patent Docket P1748R1

Election / #10
4-01-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of DeSavauge, F. et al. Serial No.: 09/692,504 Filed: October 18, 2000 For: TYPE I CYTOKINE RECEPTOR TCCR	Group Art Unit: 1644 Examiner: Roark, Jessica H. 
--	---

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 C.F.R. §1.121

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement dated March 4, 2002, please consider the following election and remarks.

Election:

Applicants received a Communication from the U.S. Patent and Trademark Office dated March 4, 2002, which contained a requirement for restriction in connection with the application captioned above. More specifically, the Examiner has required a restriction under 35 U.S.C. § 121 to one of the following inventions:

- Group I: Claims 1-5 (in part) and 6, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is a small molecule, classified in Class 514, subclass 1;

09/692,504

Patent Docket P1748R1

- Group II: Claims 1-5 (in part), 7 (in part) and 8, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is an **RNA antisense oligonucleotide**, classified in Class 514, subclass 44;
- Group III: Claims 1-5 (in part), 7 (in part) and 9, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is an **DNA antisense oligonucleotide**, classified in Class 514, subclass 44;
- Group IV: Claims 1-5 (in part) and 10, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is a **TCCR variant lacking biological activity**, classified in Class 424, subclass 184.1;
- Group V: Claims 1-5 (in part) and 11-13, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is an **antibody or antibody fragment**, classified in Class 424, subclass 130.1;
- Group VI: Claims 1-5 (in part) and 14, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is a **TCCR ligand**, classified in Class 424, subclass unknown, possibly 85.1;
- Group VII: Claims 15-20 (in part) and 21, drawn to a method of inhibiting differentiation of T cells into a Th2 subtype or treating a Th2-mediated disease by administering/contacting with a TCCR agonist that is a **small molecule**, classified in Class 514, subclass 1;
- Group VIII: Claims 15-20 (in part), 22 and 26, drawn to a method of inhibiting differentiation of T cells into a Th2 subtype or treating a Th2-mediated disease by administering/contacting with a TCCR agonist that is a **TCCR polypeptide or variant thereof (including TCCR ECD) having biological activity**, classified in Class 424, subclass 184.1;
- Group IX: Claims 15-20 (in part) and 23-25, drawn to a method of inhibiting differentiation of T cells into a Th2 subtype or treating a Th2-mediated

09/692,504

Patent Docket P1748R1

disease by administering/contacting with a TCCR agonist that is an antibody or antibody fragment, classified in Class 424, subclass 130.1;

- Group X: Claim 27, drawn to a method for determining the presence of a TCCR polypeptide in a cell using an anti-TCCR antibody, classified in Class 435, subclass 7.1;
- Group XI: Claim 28, drawn to a method for diagnosing by detecting the level of a gene encoding a TCCR polypeptide, classified in Class 435, subclass 6; and,
- Group XII: Claims 29-34, drawn to a method for identifying a compound capable of inhibiting expression or the biological activity of a TCCR polypeptide, classified in Class 435, subclass 7.8.

The Communication from the U.S. Patent and Trademark Office dated March 4, 2002, further required the election of a single disclosed species to which the claims would be restricted if no generic claim is finally held to be allowable.

Applicants hereby elect to prosecute the invention of Group V, Claims 1-5 (in part) and 11-13, drawn to a method of enhancing differentiation of T cells into a Th2 subtype or treating a Th1-mediated disease by administering/contacting with a TCCR antagonist that is an antibody or antibody fragment. In addition, in the event that no generic claim is eventually held to be allowable, Applicants further elect to prosecute the species related to inflammatory bowel disease.

REMARKS

Applicants reserve their rights to file divisional applications for the non-elected claims, as well as any other matter disclosed in the present application which is not encompassed by the elected claims.



RESTRICTION ELECTION FACSIMILE TRANSMISSION OFFICIAL

FAX RECEIVED

DATE: MARCH 29, 2002

APR 01 2002

FROM/ATTORNEY: ATULYA R. AGARWAL, PH.D., REG. NO. 40,887 GROUP 1600

FIRM: GENENTECH, INC.

PAGES, INCLUDING COVERSHEET: 5

PHONE NUMBER: (650) 225-4463

TO EXAMINER: JESSICA H. ROARK

ART UNIT: 1644

SERIAL NUMBER: 09/692,504

FAX/TELECOPIER NUMBER: (703) 308-4315

**PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY
FOR RESPONSES TO RESTRICTIONS.**

COMMENTS: _____

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30, THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SHOULD BE RETURNED TO THE PATENT AND TRADEMARK OFFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.